Figure 2
Idelalisib/BI 836826 efficacy in SP and non-SP B leukemic cells from relapsed patients. (a) SP cells were analysed as described from frozen lymph node and blood PBMC samples2 (n=5). (b) In vitro antibody-induced B-cell depletion: fresh PBMC were incubated with or without Idelalisib (0.5 μM) in the presence BI 836826 or BI 836847 (isotypic control) (10 μg/ml) for 7 days (n=12). (c) Idelalisib-induced lymphocytosis: blood lymphocytosis was quantified in Idelalisib-treated patients at different time of treatment (n=12). (d) In vitro antibody-induced B-cell depletion at pretreatment and at peak of lymphocytosis (n=10). (e) Fold change of SP and non-SP in blood samples of Idelalisib treated patients (n=5). Fold change= ratio of SP or non-SP absolute number at peak of lymphocytosis vs pretreatment. (f) In vitro antibody-induced B-cell depletion in SP and non-SP populations at peak of lymphocytosis (n=5). Experiments were done as described in Figure 1. Flow cytometric assays were done on a BDLSR2 or FORTESSA X20 (Becton Dickinson) and analysed by DIVA software. Statistical analysis: paired Student t-test. *P<0.05; **P< 0.001; ***P<0.005; ****P<0.0001.
